NCT06514768
JY231(JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia(B-ALL) No drug interventions treatment 0 recruiting NCT06346912
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL No drug interventions treatment 0 recruiting NCT06339775
Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation treatment 4 recruiting NCT05379569
Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL treatment 4 recruiting NCT04148430
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy treatment 2 active_not_recruiting NCT02050347
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) No drug interventions treatment 1 active_not_recruiting NCT03914625
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia treatment 3 active_not_recruiting NCT04544592
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL No drug interventions treatment 1 / 2 recruiting NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies No drug interventions treatment 1 not_yet_recruiting NCT06317662
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia treatment 2 not_yet_recruiting NCT06533579
Gene Therapy for B-Cell Acute Lymphoblastic Leukemia No drug interventions treatment 1 / 2 recruiting NCT06559189
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL No drug interventions treatment 1 recruiting NCT04094311
Study of Out of Specification for Tisagenlecleucel treatment 3 recruiting NCT06124157
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) treatment 3 not_yet_recruiting NCT06580301
Study of YK012 in B-cell Acute Lymphoblastic Leukemia No drug interventions treatment 1 / 2 recruiting NCT02883049
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations treatment 3 active_not_recruiting NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) treatment 1 / 2 recruiting NCT05557110
Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL treatment 2 completed NCT05602194
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma supportive_care 3 recruiting NCT05667506
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) treatment 1 / 2 recruiting NCT06608732
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. treatment 2 recruiting NCT06450067
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia No drug interventions Not Available Not Available recruiting NCT02877303
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia treatment 2 recruiting NCT06343090
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients No drug interventions treatment Not Available recruiting NCT04872790
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia treatment 1 recruiting NCT04556084
Blinatumomab Bridging Therapy treatment 2 recruiting NCT05639179
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL No drug interventions treatment 1 / 2 recruiting NCT05460533
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) treatment 2 recruiting NCT03233854
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies treatment 1 active_not_recruiting NCT03281551
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma No drug interventions treatment 1 unknown_status NCT05470777
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL No drug interventions treatment 1 / 2 recruiting NCT05379647
Natural Killer (NK) Cell Therapy for B-Cell Malignancies treatment 1 recruiting NCT05016947
Venetoclax Plus Inotuzumab for B-ALL treatment 1 recruiting NCT06389305
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction No drug interventions treatment Not Available not_yet_recruiting NCT04150497
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) treatment 1 / 2 recruiting NCT03441061
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease treatment 2 recruiting NCT03150693
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia treatment 3 suspended NCT05157971
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia treatment 1 active_not_recruiting NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers No drug interventions treatment 1 recruiting NCT01207388
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) treatment 2 completed NCT04746209
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT treatment 2 recruiting NCT06393985
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL treatment 2 not_yet_recruiting NCT06056752
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia treatment 1 recruiting NCT02746952
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia No drug interventions treatment 1 completed NCT03666000
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL treatment 1 recruiting NCT06034275
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies No drug interventions treatment 1 recruiting NCT05674175
Co-administration of CART22-65s and huCART19 for B-ALL No drug interventions treatment 1 / 2 recruiting NCT04129099
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL No drug interventions treatment 0 unknown_status NCT06078306
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). treatment 2 recruiting NCT03638206
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies No drug interventions treatment 1 / 2 unknown_status NCT02435849
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients treatment 2 completed NCT03825718
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL No drug interventions treatment 0 completed NCT05648019
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol No drug interventions treatment 2 recruiting NCT05082519
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL No drug interventions supportive_care 2 recruiting NCT04191941
Treatment of Hematological Malignancy With Novel CAR-T Cells. No drug interventions treatment 0 unknown_status NCT03856216
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation treatment 2 recruiting NCT03000335
Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk No drug interventions Not Available Not Available unknown_status NCT03488225
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia treatment 2 terminated NCT06027957
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia No drug interventions treatment 1 recruiting NCT02538926
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma treatment 2 withdrawn NCT04289220
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia No drug interventions treatment 1 unknown_status NCT03671460
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. No drug interventions treatment 1 unknown_status NCT05310591
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence treatment 1 / 2 recruiting NCT04595162
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL No drug interventions treatment 1 not_yet_recruiting NCT05130489
CAR T Cell Therapy Related Cardiovascular Outcomes No drug interventions Not Available Not Available completed NCT03982992
Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab treatment 2 withdrawn NCT05303792
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma treatment 2 recruiting NCT03504644
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia treatment 1 / 2 recruiting NCT05571540
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL No drug interventions treatment 1 / 2 withdrawn NCT02968472
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia No drug interventions treatment 1 unknown_status NCT03574168
CD19-CAR-T Cells in Patients With R/R B-ALL No drug interventions treatment 1 unknown_status NCT03876769
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients treatment 2 active_not_recruiting NCT06581081
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia, a Prospective, Open, Multicenter, Randomized, Control Study No drug interventions treatment Not Available not_yet_recruiting NCT04977895
Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia No drug interventions Not Available Not Available recruiting NCT06507514
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL treatment 1 recruiting NCT06326008
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial No drug interventions treatment 1 not_yet_recruiting NCT05333302
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma treatment 1 recruiting NCT01974479
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia treatment 1 suspended NCT02924753
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). treatment 1 unknown_status NCT03007147
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia treatment 3 active_not_recruiting NCT06220097
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies treatment 2 recruiting NCT03509961
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL No drug interventions treatment 2 recruiting NCT04747093
Induced-T Cell Like NK Cells for B Cell Malignancies No drug interventions treatment 1 / 2 unknown_status NCT06081478
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT05210907
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia No drug interventions treatment 1 recruiting NCT06009107
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) treatment 1 / 2 not_yet_recruiting NCT02618109
Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia No drug interventions other 4 terminated NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT03467256
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL treatment 1 / 2 active_not_recruiting NCT03959085
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy treatment 3 recruiting NCT04156659
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL treatment 2 withdrawn NCT04557436
TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) No drug interventions other 1 completed NCT03595917
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML treatment 1 recruiting NCT04448834
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL treatment 2 withdrawn NCT02767934
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia treatment 2 terminated NCT04534634
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL） No drug interventions treatment 2 recruiting NCT02146924
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia No drug interventions treatment 1 active_not_recruiting NCT02228096
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients treatment 2 completed NCT02828358
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement treatment 2 active_not_recruiting NCT04844086
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies No drug interventions treatment 1 terminated NCT04264039
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies treatment 0 unknown_status NCT02484430
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia treatment 2 active_not_recruiting NCT05613348
CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma No drug interventions treatment 1 / 2 withdrawn NCT05747157
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research No drug interventions treatment 0 recruiting NCT03962465
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL treatment 1 active_not_recruiting NCT03825731
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL No drug interventions treatment 0 unknown_status NCT05262673
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL No drug interventions treatment 1 recruiting NCT05707273
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission treatment 1 recruiting NCT02167360
Study of Efficacy and Safety of CTL019 in Adult ALL Patients treatment 2 withdrawn NCT03854994
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia treatment 1 unknown_status NCT06080191
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL No drug interventions treatment 1 recruiting NCT05651191
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL No drug interventions treatment 0 recruiting NCT00289562
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia treatment 1 / 2 completed NCT06559644
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia No drug interventions treatment 0 not_yet_recruiting NCT03241940
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies treatment 1 recruiting NCT02730312
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies treatment 1 completed NCT04184414
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies No drug interventions treatment 0 unknown_status NCT02458014
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease treatment 2 active_not_recruiting NCT02143414
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia treatment 2 active_not_recruiting NCT03289455
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) treatment 1 / 2 completed NCT05559450
Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL treatment 2 recruiting NCT01406756
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia treatment 3 recruiting NCT05397496
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT06137118
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia treatment 1 / 2 recruiting NCT05513612
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies treatment 1 withdrawn NCT04166838
The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) No drug interventions treatment 0 unknown_status NCT05480449
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) No drug interventions treatment 1 / 2 recruiting NCT01866839
Preventing Stem Cell Transplant Complications With a Blood Separator Machine No drug interventions treatment 1 / 2 completed NCT04437420
Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90 No drug interventions Not Available Not Available unknown_status NCT04512716
Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma No drug interventions treatment 0 recruiting NCT05621291
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu... No drug interventions diagnostic Not Available recruiting NCT06579469
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy No drug interventions Not Available Not Available not_yet_recruiting NCT03448393
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies treatment 1 recruiting NCT05442515
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies treatment 1 / 2 recruiting NCT04088890
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies treatment 1 active_not_recruiting NCT04792593
Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia No drug interventions treatment Not Available unknown_status NCT03751709
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL treatment 1 active_not_recruiting NCT01209286
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) treatment 2 completed NCT01290120
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma treatment 2 completed NCT02315612
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies No drug interventions treatment 1 active_not_recruiting NCT02328014
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies treatment 1 / 2 active_not_recruiting NCT05350787
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL No drug interventions treatment 1 unknown_status NCT04546893
Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia No drug interventions treatment Not Available unknown_status NCT04318678
CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) treatment 1 active_not_recruiting NCT05350852
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL No drug interventions treatment 1 unknown_status NCT04546906
Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia No drug interventions treatment Not Available unknown_status NCT04781634
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL treatment 1 / 2 recruiting NCT06504186
The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation prevention Not Available not_yet_recruiting NCT04499573
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL treatment 1 / 2 active_not_recruiting NCT03559439
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies No drug interventions treatment 1 unknown_status NCT03156790
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia treatment 2 recruiting NCT04723901
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia No drug interventions treatment 1 / 2 unknown_status NCT01219816
Multi-centric Study treatment 2 completed